Johnson & Johnson (J&J) has received approval from the European Commission (EC) for its subcutaneous (SC) Darzalex (daratumumab)-based quadruplet regimen in newly diagnosed multiple myeloma (MM).

Amgen has shared positive results from a late-stage study of its immunotherapy Imdelltra (tarlatamab-dlle) in small cell lung cancer (SCLC). The global DeLLphi-304 trial has been comparing the drug ...

Advanced melanoma patients in England are set to be fast-tracked into a clinical trial of a new skin cancer vaccine after the NHS partnered with Oxford-based Scancell to widen access across the ...

Equipping patients, carers and loved ones with the tools and understanding to make the choices that are right for them ...

Roche’s Columvi (glofitamab) has been approved by the European Commission (EC) as part of a combination treatment for diffuse ...

London became the first UK health agency to gain B-Corp accreditation. CEO and Co-Founder, Matt Hunt reports back on life in ...

Bristol Myers Squibb (BMS) has announced that its dual immunotherapy combination has been approved by the US Food and Drug ...

AstraZeneca’s (AZ) AKT inhibitor Truqap (capivasertib) has been recommended by the National Institute for Health and Care Excellence (NICE) as part of a combination treatment for advanced breast ...

AstraZeneca (AZ) and Daiichi Sankyo’s Datroway (datopotamab deruxtecan) has been approved by the European Commission (EC) for ...

Johnson & Johnson (J&J) has announced that an injectable version of Rybrevant (amivantamab) has been approved by the European Commission (EC) for two advanced non-small cell lung cancer (NSCLC) ...

AbbVie’s Rinvoq (upadacitinib) has been granted marketing authorisation by the European Commission (EC) to treat giant cell ...

Bristol Myers Squibb (BMS) has announced that its dual immunotherapy combination has been approved by the US Food and Drug ...